Trade BioNTech BNTX

Sell
 Buy

BioNTech live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

BioNTech News

Emma Rose 2025 Aug 27, 04:10

SpaceX's Starship Achieves Success: A Look at the Future and Remaining Challenges

Noah Lee 2025 Aug 27, 02:10

Hedge Funds Short VIX at Record Levels: Is Market Calm a Mirage?

Frances Wang 2025 Aug 26, 16:00

Crypto Price predictions: BTC, ETH, XRP, BNB, SOL

crypto
Frances Wang 2025 Aug 26, 16:00

ETF CFD Trading Platforms: Oanda, markets.com, ATFX, AvaTrade

etfs
Ghko B 2025 Aug 26, 16:00

Nasdaq Index Overview: How to Trade Nasdaq CFD with markets.com?

indices cfd trading
Tommy Yap 2025 Mar 04, 16:00

Week Ahead: U.S. Inflation Data and BoC Policy Rate in Focus

Forex Indices
Moderna Share Price
Georgy Istigechev 2024 Jan 03, 08:01

Moderna share price jumps as Oppenheimer upgrades stock

Shares
Pfizer shares sink as revenue prospects
Georgy Istigechev 2023 Dec 14, 05:13

Pfizer shares sink on lower COVID revenue prospects

Shares
shutterstock_1781525795.jpg
Zachariah Walker 2023 Feb 14, 09:11

5 Stocks to Fall in Love with this Valentines Day

2021 Aug 24, 08:05

Stocks make further gains as oil bounce carries on

Latest news

Show more
Sophia Claire 2025 Aug 27, 13:20

EU Eyes Tariff Removal on US Goods Amid Trade Deal Push

Noah Lee 2025 Aug 27, 09:20

Asian Markets Ease Gold ETF Restrictions Amid Geopolitical Uncertainty

Ava Grace 2025 Aug 27, 08:20

Russia's Economic Dilemma: Will the Ukraine War Push Towards Peace?

Ava Grace 2025 Aug 27, 07:20

Goldman Sachs Predicts Oil Prices to Plunge to $50s by 2026: Analyzing the Forecast

Noah Lee 2025 Aug 27, 06:20

Cryptocurrency in Venezuela: An Economic Lifeline Amidst Hyperinflation and Sanctions

Liam James 2025 Aug 27, 06:20

Cambricon Shares Surge Amidst AI Chip Demand

Emma Rose 2025 Aug 27, 05:20

US Tariffs on India: Economic Impact and Analysis

Liam James 2025 Aug 27, 03:20

Iran Nuclear Deal Talks Stall: UN Sanctions Revival Looms

Info

Spread

1.3360

Spread (%)

1.3098 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Market open

Wednesday

13:31 - 19:59

Monday

13:31-19:59

Tuesday

13:31-19:59

Thursday

13:31-19:59

Friday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

25258723328

Shares Outstanding

240399008

Earnings Date (Next)

0000-00-00

Div Yield

2022-06-17

Ex-Dividend Date

2022-06-02

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-1.66

Learn more about this instrument

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Frances Wang 2025 Aug 26, 16:00

Active Stocks Overview: NVDA stock, TSLA stock, BA Stock, RTX

Stocks
Ghko B 2025 Aug 26, 16:00

Benefits of CFD Trading: CFD Trading Explained with Examples

CFD Trading
Ghko B 2025 Aug 26, 16:00

CFD Trading Brokers with Bonus: AvaTrade, eToro, Plus500, XM

CFD Trading
Trustpilot